Literature DB >> 7795507

Mortality among HIV-infected intravenous drug addicts in Stockholm in relation to methadone treatment.

A Fugelstad1, J Rajs, M Böttiger, M Gerhardsson de Verdier.   

Abstract

The aim of the study was to estimate the mortality rate and evaluate the causes of death in all diagnosed HIV-positive IDUs in the Stockholm area, 1986-90, and to compare the risk of death of those who received methadone treatment with that of those never admitted to or discharged from the programme. Data were collected from the Swedish National Bacteriological Laboratory, the Methadone Maintenance Programme (MMTP) and the Department of Forensic Medicine, as well as from hospitals in the Stockholm region. In Sweden 90% of all IDUs are HIV-tested. Most deceased IDUs are examined forensically. This examination always includes HIV-testing. During the observation period, 472 HIV-infected IDUs were reported from the Stockholm area. Of these addicts 135 participated in the methadone maintenance programme for a shorter or longer time during the study period. Most of them had received the HIV-diagnosis more than 1 year before first entering the programme. Sixty-nine subjects died during the observation period. A majority, 52 persons, died from violence or poisoning. Seventeen died from somatic complications of drug abuse. Nine of them were diagnosed as suffering from AIDS. Eight of the deceased had participated in the MMTP. The relative risk of death from external violence and poisoning was 0.25 (95% confidence interval 0.1-1.0) when participants in the MMTP were compared with HIV-infected IDUs never attending the programme. When all causes of death are compared the relative risk was 0.8. Those patients discharged from the programme have a higher mortality rate than those who never participated.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795507     DOI: 10.1046/j.1360-0443.1995.90571112.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  8 in total

Review 1.  Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS.

Authors:  L Degenhardt; W Hall; M Warner-Smith
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

2.  The impact of harm-reduction-based methadone treatment on mortality among heroin users.

Authors:  M W Langendam; G H van Brussel; R A Coutinho; E J van Ameijden
Journal:  Am J Public Health       Date:  2001-05       Impact factor: 9.308

Review 3.  Mortality among people who inject drugs: a systematic review and meta-analysis.

Authors:  Bradley M Mathers; Louisa Degenhardt; Chiara Bucello; James Lemon; Lucas Wiessing; Mathew Hickman
Journal:  Bull World Health Organ       Date:  2013-02-01       Impact factor: 9.408

Review 4.  Heroin overdose: research and evidence-based intervention.

Authors:  Shane Darke; Wayne Hall
Journal:  J Urban Health       Date:  2003-06       Impact factor: 3.671

Review 5.  Examining non-AIDS mortality among people who inject drugs.

Authors:  Bradley M Mathers; Louisa Degenhardt
Journal:  AIDS       Date:  2014-11       Impact factor: 4.177

6.  Malmö Treatment Referral and Intervention Study-High 12-Month Retention Rates in Patients Referred from Syringe Exchange to Methadone or Buprenorphine/Naloxone Treatment.

Authors:  Martin Bråbäck; Lars Ekström; Katja Troberg; Suzan Nilsson; Pernilla Isendahl; Louise Brådvik; Anders Håkansson
Journal:  Front Psychiatry       Date:  2017-08-31       Impact factor: 4.157

Review 7.  Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.

Authors:  Luis Sordo; Gregorio Barrio; Maria J Bravo; B Iciar Indave; Louisa Degenhardt; Lucas Wiessing; Marica Ferri; Roberto Pastor-Barriuso
Journal:  BMJ       Date:  2017-04-26

8.  What lessons from Sweden's experience could be applied in the United States in response to the addiction and overdose crisis?

Authors:  Anna Fugelstad
Journal:  Addiction       Date:  2022-05       Impact factor: 7.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.